The enzymatically inactive mutant exhibits cancer in two-step process: in the first phase, it disturbs the interaction of HER2 with other receptors in this family (EGFR, ErbB3) as well as other tyrosine kinase receptors (MET, IGF-1R). This evidence concerns the gene EGFR and cancer.